How Does Revvity Company Work?

Revvity Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How does Revvity drive value across life‑sciences and diagnostics?

In 2023 PerkinElmer’s life‑sciences and diagnostics units rebranded as Revvity, creating a pure‑play focused on reagents, instruments and informatics. By 2024 it reached 190+ countries with a growing reagents footprint and multi‑omics software supporting discovery to clinical testing.

Revvity combines recurring consumables (reagents, assays), regulated diagnostics and informatics to generate resilient cash flow, while instruments and pharma funding cycles add volatility. Its go‑to‑market links sample prep, imaging, NGS and newborn screening into end‑to‑end workflows.

How does Revvity Company work? It monetizes installed base through consumables and software, sells instruments to expand market share, and leverages diagnostics for stable, regulated revenue; see Revvity Porter's Five Forces Analysis for competitive dynamics.

Revvity creates value by delivering end‑to‑end life‑science and diagnostics workflows—reagents, instruments, software, and services—across genomics, proteomics, imaging and clinical testing, linking research to high‑confidence diagnostics and population screening.

Core product scope

Revvity supplies NGS library prep kits, high‑throughput assays (Alpha, DELFIA), immunoassay reagents, cell imaging systems, and clinical diagnostics for reproductive, infectious and metabolic disorders.

Integrated informatics

Signals analytics, imaging analysis and data‑management tools reduce time‑to‑result and lower total cost of ownership for labs and screening programs.

Operations model

Operations combine in‑house manufacturing of assay chemistries, specialized instrument assembly, a global components supply chain and IVD quality/regulatory systems to support clinical deployment.

Go‑to‑market

Sales mix is hybrid: direct enterprise for pharma and health systems, e‑commerce for catalog reagents, channel partners for emerging markets, and installed‑base field service for consumable revenue.

Core customer segments include biopharma R&D and QC, CROs/CMOs, academic/government research, clinical labs and public health programs (notably newborn screening) and industrial testing.

Competitive differentiators

Revvity’s value proposition rests on breadth (research→diagnostics), high consumable attach rates, assay chemistry IP, regulatory expertise and informatics‑enabled workflows.

• Recurring consumables tied to installed instruments drive predictable revenue and service lifetime value.
• Assay IP and chemistry platforms (e.g., NEXTFLEX NGS kits) protect margins and enable premium pricing.
• Regulatory capability supports neonatal and public‑health screening; Revvity‑linked programs are estimated to screen 30M+ newborns annually using its assays/instruments.
• Strategic partnerships with sequencing vendors, reference labs and public health agencies enable end‑to‑end workflow integration and country‑scale screening.

Financial and operational levers include recurring consumable sales, enterprise instrument placements, service contracts, software subscriptions and program‑level contracts with health agencies; these form the primary revenue streams and underpin the Revvity business model and how Revvity works at scale. Read more in the Growth Strategy of Revvity

Revvity SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Revenue Streams and Monetization Strategies for Revvity centre on recurring consumables, instrument sales, diagnostics, software subscriptions and services, with validated workflows and multi‑year contracts driving predictability and margin expansion.

Consumables and Reagents

Consumables like assay kits, NGS sample‑prep, antibodies and detection reagents represented the majority of revenue in 2024–2025, accounting for roughly 60–65% of sales and providing stable, recurring cash flow tied to installed instruments and validated workflows.

Instruments and Imaging Systems

High‑content imagers, plate readers, automation and diagnostic analyzers made up about 15–20% of revenue; instrument cycles are lumpy but crucial for future consumables pull‑through and installed‑base expansion.

Diagnostics Test Kits & IVD

Newborn screening, infectious disease and reproductive health assays contributed roughly 15–20% of revenue, often under long‑term public health and laboratory contracts that smooth demand and increase government/health‑system exposure.

Software & Informatics

Licenses, subscriptions and analytics/image‑analysis modules accounted for about 3–5% in 2024 but are a high‑growth area as SaaS and enterprise agreements expand, improving recurring revenue mix and gross margins.

Services & Support

Instrument service contracts, validation, training, lab services and custom assay development made up roughly 5–7% of revenue, supporting customer retention and lifecycle monetization.

Monetization Mechanics

Revenue strategy emphasizes validated workflows to lock in reagent pull‑through, multi‑year service contracts, tiered software pricing and instrument+consumable+informatics bundles to boost lifetime value.

Regional and product mix dynamics affect monetization and growth trajectories.

Regional, Market and Post‑Pandemic Trends

North America and EMEA remain the largest markets, APAC is growing faster; diagnostics revenues skew toward government and health systems while tools serve biopharma and academia. COVID‑related revenues fell sharply in 2023–2024; core life‑science reagents and newborn screening rebased to low‑ to mid‑single‑digit growth in 2024, with informatics and NGS sample‑prep outpacing the portfolio.

• Consumables drive recurring revenue and accounted for 60–65% of 2024–2025 revenue.
• Instruments represented ~15–20%, enabling future consumables demand.
• Diagnostics and IVD comprised ~15–20%, often under long‑term contracts.
• Software grew to ~3–5% and is expanding via SaaS deals.
• Services added ~5–7%, improving retention and margins.

Related reading: Mission, Vision & Core Values of Revvity

Revvity PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Key milestones from 2022–2025 show a focused pivot: separation and rebrand in 2022–2023 sharpened the Revvity company toward life science tools and diagnostics; subsequent years prioritized NGS, multi‑omics, imaging, newborn screening scale‑up, software acceleration, and mix‑shift actions to raise recurring revenue and margins.

Separation and Rebrand (2022–2023)

The 2022–2023 separation created a pure‑play life sciences entity; portfolio pruning generated cash used to de‑leverage and reinvest into core diagnostics and research tools.

NGS and Multi‑omics Expansion (2023–2024)

Expanded NGS sample‑prep and multi‑omics workflows, plus enhanced imaging and high‑content analysis, targeting genomics and translational research customers.

Software and Pharma Partnerships (2024)

Accelerated data‑management and image‑analysis modules and deepened pharma collaborations for screening and biomarker discovery; supply chain normalized after pandemic disruptions.

Mix‑Shift and Margin Actions (2024–2025)

Actions to increase recurring revenue and improve gross margin included insourcing critical reagents and optimizing manufacturing footprint to improve unit economics.

Operational and market context: Revvity products and services capitalized on an installed base of instruments that drive sticky consumables; regulatory credibility in newborn screening and select IVD niches underpins recurring revenue and cross‑sell opportunities.

Competitive Edge and Responses to Headwinds

Competitive advantages include validated assays, proprietary detection chemistry/IP, breadth from discovery to diagnostics, and a growing informatics layer connecting instruments and data; management reallocated R&D toward secular growth areas.

• Installed base drives consumables revenue and recurring streams
• Regulatory approvals and neonatal screening leadership create durable niche positions
• Chemistry/IP supports differentiated detection and assay performance
• Informatics and software enable cross‑sell and higher-margin digital services

Financial and operational facts: post‑separation proceeds were used to reduce leverage; by 2024–2025 mix shift and insourcing aimed to lift gross margins several hundred basis points and increase recurring revenue share; newborn screening scale‑ups expanded geographic coverage, contributing to higher annuity‑like revenue. Read more in the company market note: Target Market of Revvity

Revvity Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Revvity's industry position blends diagnostics strength and life‑science tools, with leadership in newborn screening kits and high‑content imaging; risks include capital spending slowdowns, pricing pressure in tenders, and IVD regulatory shifts; strategic priorities for 2025–2027 target NGS prep, single‑cell and imaging, SaaS informatics, and disciplined M&A to drive margin and recurring revenue growth.

Industry Position

Revvity competes with Thermo Fisher, Danaher, Agilent, Bruker and Illumina‑adjacent ecosystems in instruments and reagents, and with PerkinElmer peers, bioMérieux and Roche Diagnostics in select IVD niches. Market share is strongest in newborn screening where Revvity is one of the top global providers of MS/MS and immunoassay kits and instruments, and in selected detection chemistries and high‑content imaging.

Competitive Advantages

Customer loyalty is anchored by assay validation, regulatory approvals and long validation cycles, creating high switching costs; recurring consumables and validated workflows support stable revenue streams and stickiness across clinical and research customers.

Key Risks

Principal risks include slower biopharma capital spending and elongated academic funding cycles, pricing pressure in public‑health tenders, EU IVDR and potential FDA LDT oversight changes, supply‑chain and raw‑material variability, and competitive pricing from large scale players. Technological disruption in sequencing prep and spatial/phenotypic analysis also threatens incumbent positions.

Financial and Operational Targets

Management targets a higher recurring revenue mix and margin expansion through favorable mix and productivity gains; the company aims to sustain mid‑single‑digit organic growth and expand cash generation to reinvest in R&D and targeted acquisitions between 2025 and 2027.

Key strategic moves focus on expanding NGS and multi‑omics prep, advancing imaging and single‑cell/phenotypic screening, scaling SaaS informatics offerings, and deepening public‑health diagnostics to offset cyclicality and improve gross margins and recurring revenue share.

Near‑term Priorities and Metrics

Execution priorities for 2025–2027 concentrate on technology adjacencies and commercial scale to drive higher margin mix and recurring revenue. Public filings and investor commentary through 2024–2025 indicate management expects margin expansion and disciplined M&A to fill capability gaps.

• Expand NGS/multi‑omics prep and library kits to capture sequencing‑adjacent spend
• Scale SaaS informatics to increase recurring revenue and data‑services penetration
• Invest in imaging, single‑cell and phenotypic screening platforms to defend high‑value niches
• Pursue disciplined M&A to acquire complementary tech and broaden diagnostics portfolio

For deeper context on strategy and go‑to‑market, see the company overview in this Marketing Strategy of Revvity.

Revvity Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔